A subgroup of streptococcal bacteria, known as ‘StrepA’, kills over 500,000 people and causes over 700 million infections annually worldwide. StrepA shows increasing antibiotic resistance but, despite the high incidence rate, there is no StrepA vaccine, and this has been made a WHO priority. With our established and patented innovative glycoconjugate vaccine production platform, RHAPSEDA will lead the field and be the first to recombinantly produce universal multivalent StrepA vaccine candidates. Our platform bypasses a number of highly complex chemical synthesis steps, significantly cutting production costs. The platform may also be applicable to vaccines for other streptococcal subgroups.